Upbeat outlook for health industry on rising demand
UOBKH Research noted that the hospital segment, in particular, stands out with an earnings growth forecast of 15.1% this year.
PETALING JAYA: UOB Kay Hian Research (UOBKH Research) has upgraded the Malaysian healthcare sector to 'overweight,' citing a combination of compelling valuations, strong earnings momentum and 'diminishing policy risk' – with KPJ Healthcare Bhd and Duopharma Biotech Bhd flagged as top picks.
In a sectoral update report, the research house said the industry's earnings are 'highly defensive yet attractive, against a backdrop of diminishing policy risk.
'The sector is also supported by structural positives, robust rollouts and resilient domesticated demand,' it said.
UOBKH Research noted that the hospital segment, in particular, stands out with an earnings growth forecast of 15.1% this year.
This, it said, is against a backdrop of valuations that are currently trading one standard deviation below the sector's five-year mean price-to-earnings ratio.
It also sees margin tailwinds as both IHH Healthcare Bhd and KPJ are in the early stages of brownfield expansions.
'These positives far outweigh diminishing policy risk,' it said.
Beyond hospitals, UOBKH Research also highlighted non-hospital plays such as Alpha IVF Group Bhd and Duopharma Biotech Bhd for their respective growth drivers. 'Alpha IVF is undertaking exciting regional expansion while Duopharma is expected to see a sharp input cost-led recovery in 2025.'
On the policy front, UOBKH Research does not anticipate major disruptions from the planned introduction of a diagnosis-related group (DRG) payment model by year-end, which will initially apply to a 'limited set of simple medical conditions'.
'As a fixed-rate payment model, DRG represents a shift towards value-based care – a direction private hospitals are already moving towards.
'Hence, we do not expect future DRG rollouts to significantly disrupt the operating landscape,' it said.
The research firm also downplayed the potential impact of the new drug price transparency rule for private healthcare facilities.
'We believe the drug price display mandate is unlikely to deter patients from purchasing medications directly from their doctors.
'A more impactful measure would be dispensing separation – where doctors prescribe and pharmacists dispense – but this has yet to be formally considered by the Health Ministry.'
Similarly, the research house expects 'minimal' impact from the 6% sales and service tax (SST) on private healthcare services for foreigners, which takes effect from July 1, 2025.
'The overall impact is expected to be minimal, as foreign patient revenue accounts for approximately 6% of KPJ's and 1% of IHH's total revenue.
'While foreign patients contribute around 50% of Alpha IVF's revenue, its niche in offering specialised, high-end in vitro fertilisation treatments suggests that demand will likely remain resilient despite the SST expansion.'
UOBKH Research named KPJ and Duopharma as its top picks, 'driven by the former's multitude of levers to drive robust earnings growth and the latter's expected cost-led recovery in 2025'.
'In summary, attractive earnings growth, compelling valuations and ongoing positive structural changes support our 'overweight' rating for the healthcare sector.
'In addition, the sector is highly defensive, insulated from external trade that is at risk of a global economic slowdown.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
33 minutes ago
- New Straits Times
SST preferred over GST to reduce people's burden: Johan Merican
KUALA LUMPUR: The government has chosen to maintain the Sales and Service Tax (SST), instead of reintroducing the Goods and Services Tax (GST), in order to reduce the tax burden on the people. Treasury secretary-general Datuk Johan Mahmood Merican said while GST is a more efficient and comprehensive tax system, it ultimately places a heavier burden on end consumers. "GST has its strengths. It is broad-based, covers nearly all goods and services, and applies at every stage of the supply chain. From a revenue collection perspective, it is very effective because it captures the entire economy. "However, under GST, the final tax burden falls entirely on the rakyat. Businesses can claim back the GST they pay, but the end consumer cannot," he said. Johan was speaking during a TikTok Live hosted by the Finance Ministry titled 'SST Naik, Semua Harga Pun Naik?', aimed at addressing public concerns over the upcoming expanded SST and its implications. Johan explained that while SST is less efficient from a taxation standpoint and does not cover as wide a range of economic activities as GST, it imposes less financial pressure on the public. "SST has been part of our tax system since the 1970s, so it is familiar and easier to implement. It is also more targeted, as we avoid taxing essential goods and focus more on taxing businesses," he said. Johan noted that the government aims to collect an additional RM10 billion in revenue under the SST system. By comparison, reinstating GST with its previous framework could bring in more than RM20 billion. "From a business point of view, GST may be preferred because companies can claim back the tax paid. But some businesses may find SST burdensome, as they have to absorb the tax without the ability to recover it," he said. He added that the government's decision reflects a balancing act between raising national revenue and safeguarding the rakyat from higher living costs. "Even though SST may be less efficient in terms of tax collection, it allows us to minimise the impact on consumers. "That's why we've chosen to expand SST rather than reintroduce GST for now," Johan said.
The Star
an hour ago
- The Star
KPJ Healthcare aims 70% business volume from age-related, NCD cases this year
KUALA LUMPUR: KPJ Healthcare Bhd expects age-related and non-communicable disease (NCD) cases to contribute about 70 per cent of its business volume this year. Its president and managing director Chin Keat Chyuan said that currently, about 15 per cent of Malaysia's general population is aged 60 and above. "Age comes with many associated diseases like NCDs, the three highs that we always talk about, namely high blood sugar, high cholesterol, and high blood pressure. "And all these lead to many potential issues, including oncology problems such as cancer, which is a major concern facing Malaysians,' he said in a press conference after KPJ Healthcare's 32nd annual general meeting and extraordinary general meeting, here today. Chin said these challenges represent opportunities for private healthcare providers to better serve the Malaysian population, including addressing international healthcare risk factors. "This represents a huge opportunity, and in 2025, KPJ will continue to expand our capacity, both in terms of the number of clinicians we have and the services we offer,' he said. He added that NCDs such as heart and lung diseases, neurological conditions, strokes, cancer, and orthopaedic issues provide KPJ with opportunities to serve patients using advanced surgical and medical solutions. Commenting on medical tourism, Chin said KPJ is also targeting patients from Indonesia. "I am also targeting the potential 20 per cent of Indonesia's 270 million population, that is 54 million people, who are currently travelling outside Indonesia, to seek treatment in countries such as Singapore, Malaysia, Thailand, and Vietnam. "And according to data from the Malaysia Healthcare Travel Council, more than 40 per cent of those Indonesian patients are coming to Malaysia, which is contributing significantly to our health tourism industry,' he said. He said that this is an immediate business opportunity, especially as the group expands its workforce and increases the number of beds in its hospitals. "We are (also) optimising all the assets we have, such as magnetic resonance imaging machines, computed tomography scanners, and other technologies we have invested in,' he added. Also present at the press conference were KPJ Healthcare chairman Tan Sri Dr Ismail Bakar and chief financial officer Mohd Khairul Izzad Mohammed Shamsudin. - Bernama
Barnama
2 hours ago
- Barnama
CPO Futures Ends Higher
By Nurunnasihah Ahmad Rashid KUALA LUMPUR, June 26 (Bernama) -- The crude palm oil (CPO) futures contract on Bursa Malaysia Derivatives ended the short week higher following lower-than-expected palm oil production pace and robust June export performance, said a commodity analyst. Mumbai-based Sunvin Group commodity research head Anilkumar Bagani said the reduction in the Malaysian palm oil export tax and the signing of the Malaysia-European Free Trade Association Economic Partnership Agreement also supported the better performance today. 'However, renewed weakness in Chicago Board of Trade soybean oil futures, lack of destination buying apart from India, stronger ringgit and the likelihood of unchanged Indonesian palm oil export taxes and levies for July capped the gains in ringgit-denominated Malaysian palm oil futures,' he told Bernama. He said the Malaysian Palm Oil Association estimated Malaysian palm oil production during the June 1-20 period, down by 4.56 per cent, in line with the UOB Kay Hian estimate of a -1 per cent to -5 per cent reduction, but production is lower than previously thought of an unchanged to two per cent decline. At the close, the spot-month July and August 2025 contracts increased by RM47 each to RM3,986 per tonne and RM4,005 per tonne, respectively, while September 2025 improved by RM46 to RM4,011 per tonne. October 2025 went up RM42 to RM4,011 per tonne, November 2025 rose by RM39 to RM4,017 per tonne, and December 2025 gained RM37 to RM4,031 per tonne. Trading volume decreased to 63,167 lots from 64,359 on Wednesday, while open interest fell to 224,560 contracts from 231,315 previously. The physical CPO price for July South increased by RM20 to RM4,020 per tonne.
